PMA device
Edwards EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Percutaneously Delivered Prostheses And Tricuspid Valves (NPW, Class III) · First FDA decision Feb 1, 2024, newest Oct 31, 2025Tricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
Breakthrough-designated
Device trials
8
Naming "Edwards EVOQUE"
MAUDE reports
0
Brand "Edwards EVOQUE", since 2015
PubMed studies
0
Mentioning "Edwards EVOQUE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Edwards EVOQUE Tricuspid Valve Replacement System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Edwards EVOQUE Tricuspid Valve Replacement SystemPMA supplement
P230013-S013 · Decided Oct 31, 2025 · 178 days after receipt · Normal 180 Day Track
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
P230013-S016 · Decided Aug 13, 2025 · 57 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
- Edwards EVOQUE Tricuspid Valve Replacement SystemPMA supplement
P230013-S010 · Decided Feb 11, 2025 · 89 days after receipt · Normal 180 Day Track
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Tricuspid Valve Replacement (TTVR)National analysisReview closedCAG-00467NUpdated Sep 24, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National analysisReview closedCAG-00468NUpdated Sep 23, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National determinationOn the books20.38Updated Jun 2, 2026
- Transcatheter Tricuspid Valve Replacement (TTVR)National determinationOn the books20.37Updated Jun 2, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Edwards EVOQUE", any status and sponsor, newest update first.
- Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid RegurgitationPivotal-lookingRecruiting
Medtronic CardiovascularPublic (MDT)
NCT07321899 · 1,186 participants (planned) · Start Sep 11, 2026 · Primary completion Sep 2031
Device: Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System; Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System · For: Severe Tricuspid Regurgitation
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
- VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)Pivotal-lookingRecruiting
VDyne, Inc.Not on our public-company list
NCT07516444 · 520 participants (planned) · Start Jul 28, 2026 · Primary completion Jun 2029
Device: Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System; Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System · For: Tricuspid Valve Regurgitation; Tricuspid Valve Disease; Cardiovascular Diseases (CVD) and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; San Francisco, California · 12 sites in all
- Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement SystemPivotal-lookingRecruiting
Laplace Interventional, IncNot on our public-company list
NCT07687485 · 700 participants (planned) · Start Sep 4, 2026 · Primary completion Sep 2029
Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System; Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System · For: Severe Tricuspid Valve Regurgitation; Tricuspid Valve Regurgitation; Tricuspid Valve Disease and 5 more
Sites: Tulsa, Oklahoma; Kingsport, Tennessee
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Edwards EVOQUE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NPW
1,088 reports: 30 malfunction, 970 injury, 88 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EOOpen, Classified
Z-2172-2026 · Started Mar 27, 2026 · Posted by FDA May 13, 2026
Reason given: Labeling update to provide warning if functionality of the valve replacement delivery system is compromised.
Cause as FDA categorized it: Labeling design · Device type: Percutaneously Delivered Prostheses And Tricuspid Valves (NPW)
Published research
The most relevant PubMed records for "Edwards EVOQUE"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NPW.
- EVOQUE Tricuspid Valve Replacement SystemEdwards Lifesciences, LLC · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.